Toll-free: (877) 631-6311 | Local: (602) 626-3100 |
Office Open
.(JavaScript must be enabled to view this email address)

Chris Wood

Chief Investment Officer, Healthcare & Biotech

Health & Biotech Market veteran

Chris Wood is Mauldin Economics’ chief investment officer for healthcare and biotech, as well as the chief investment officer at RiskHedge, a professional investment research firm focused on understanding and profiting from disruption.

A 16-year market veteran, he’s one of America’s most respected analysts and has the track record to prove it. His unique ability to consistently pinpoint stocks that double and triple has intrigued thousands of readers.


Premium Publications

Explore Chris's exclusive content for subscribers only.

Healthy Returns

Boost Your Portfolio and Live Long Enough to Enjoy the Healthy Profits

Chris Wood - Healthy Returns

Editor Chris Wood and his professional analysts pinpoint profitable investments in the booming healthcare and anti-aging sectors.

With my 15+ years of healthcare and biotech analysis experience as a professional investor, author, and tech commentator, I can identify both the specific problems heart disease poses as well as companies with viable solutions to address them.

A revolutionary therapy, maybe. Or a blockbuster drug. Or perhaps a breakthrough device. All that matters is that the solution has huge prospects for effective heart disease treatment.

And that the company behind the solution is well-positioned to deliver large returns over the next year. The company must have serious growth potential, or it’s just not good enough to make the cut in my newsletter, Healthy Returns.

Find Out More


Biotech Millionaire

The Investment Strategy Where C.A.S.H. Is King

Chris Wood - Biotech Millionaire

This premium alert service, with co-editors Chris Wood and Jake Weber at the helm, focuses on small-cap medical biotech companies with exceptional short-to mid-term profit potential. Their unique C.A.S.H. investing formula—Catalyst, Addressable Market, Science, Hype Potential—ensures that only the most promising candidates make it into the Biotech Millionaire portfolio.

In their premium alert service, they focus on small-cap, pre-revenue drug companies with exciting pipeline candidates in clinical trials. Their goal with each portfolio stock is to get at least a 100% return in the span of 12 to 24 months...

Find out more

Subscriber Comments

Monday's trading and (your recommendation’s) gain increased my portfolio in the amount of a year's wages after taxes!!!!! (...) Keep up the fantastic research!!"

Keith T.

Get in Touch

PO Box 192495,
Dallas, Texas 75219

Toll-free: (877) 631-6311
Local: (602) 626-3100

Copyright © 2021 Mauldin Economics, LLC. All rights reserved.

7 Secrets of Successful Biotech Investors

The healthcare and biotech sectors are booming like never before. But it takes finesse to lock in the outsized gains that are available to savvy investors in these sectors.

Tricks of the Trade—from Top Biotech Investors

Our 20-page report, Portfolio Boost: 7 Money-Making Tips for New Biotech Investors, tells you everything you need to know to get started. Enter your email to get your free copy today!

By signing up for this free report you agree to receive email updates on Mauldin Economics news, events, and offers.